SEATTLE, March 25, 2020 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today that its Carnation Ambulatory Monitor (“CAM™”) Patch has been chosen for use in protocols to measure QT Segments in COVID-19 patients who have been prescribed Hydroxychloroquine (HCQ).
BardyDx’s CAM Patch will be utilized in newly established protocols at hospitals across the Seattle, Washington area to monitor cardiac rhythms for COVID-19 patients on HCQ after hospital discharge, as well as for outpatients. HCQ has been demonstrated, in certain populations, to prolong the QT interval, resulting in a potentially lethal arrhythmia called Torsades de Pointes. The unique ability of the BardyDx CAM Patch to detect and record low frequency, low amplitude cardiac rhythms is especially valuable in measuring QT intervals and diagnosing Torsades de Pointes.
“The world is currently at war against the COVID-19 virus and we are proud that the CAM Patch is being used in that fight to help physicians better identify and understand any arrhythmias, or other cardiac irregularities, that may be related to use of HCQ in COVID-19 patients, as well as how any potential COVID-19 vaccines might impact cardiac function,” said electrophysiologist Gust Bardy, M.D., the founder, CEO, and Chief Medical Officer of BardyDx.